{"disease":{"id":"apol1-mediated-kidney-disease","name":"apol1 mediated kidney disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06824987","title":"Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":96,"lead_sponsor_name":"AstraZeneca","has_results":false},{"nct_id":"NCT05324410","title":"A Phase 1 Dose Escalation Study to Evaluate Safety and Pharmacokinetics (PK) of VX-840 in Healthy Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":88,"lead_sponsor_name":"Vertex Pharmaceuticals Incorporated","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}